Goldman Sachs cuts Dr. Reddy’s stock price target on margin pressure By Investing.com
Goldman Sachs cut its price target for Dr. Reddy’s Laboratories (NSE:DRRD, NYSE:RDY) to INR1,050 from INR1,075 and kept a Sell rating, citing margin pressure. The firm said FY2027 Q1 revenue fell 6% YoY to Rs80.7B and adjusted EBITDA margin was about 13%. It revised EPS estimates after the earnings miss.
How this was made
The 30-second read
Why it matters
A Sell rating with a lower PT, tied to margin compression and product-specific headwinds, can drive incremental selling or reduce dip-buying appetite until profitability trends improve.
Market read
Trader focus is on the combination of a PT cut, a Sell rating, and margin headwinds after a reported earnings miss.
What to watch
The PT change is based on sum-of-the-parts and updated EPS estimates, but the article does not quantify how quickly margin headwinds could reverse or how much of the miss is timing-related versus structural.
Background
The piece centers on Goldman Sachs revising its valuation and estimates after Dr. Reddy’s fiscal Q1 2027 revenue and margin underperformance.
Ticker impact
Goldman Sachs cut Dr. Reddy’s price target to INR1,050 from INR1,075 and kept a Sell rating amid margin pressure and an earnings miss.
Near-term bias to downside or underperformance versus peers until margins stabilize and semaglutide/lenalidomide dynamics improve.
The article provides a concrete PT cut plus a thesis tied to margin compression and product price erosion, which typically pressures sentiment even if growth guidance remains.
Market effects
Signals continued margin sensitivity in branded pharma and GLP-1-adjacent economics, with emphasis on price erosion and pipeline depth.
Highlights investor focus on India and Russia growth assumptions versus Europe and U.S. ex-Revlimid growth.
Reinforces broader caution around Ozempic/semaglutide opportunity sizing and near-to-medium term product mix.
Counterpoint
Guidance still calls for mid-teens growth in India and Russia and double-digit growth elsewhere, with semaglutide framed as incremental upside via price realizations and volume uptake.
Key entities
- public_companyDr. Reddy’s Laboratories
Subject of the analyst price target cut and discussion of revenue decline, margin pressure, and guidance.
- analyst_firmGoldman Sachs
Issuer of the price target reduction and Sell rating, citing Ozempic opportunity concerns and pipeline/margin issues.
